Skip to main content

Table 2 Response assessment by conventional imaging modalities and positron emission tomography at interim time point

From: Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients

Patient no.

Stage

Bulky disease

Histopathological subtype

Localization of leading lesion

Response assessment at interim

Follow-up

iCIM

iPET

ΔSUVmax (%)

1

III

B

lymphoblastic

Nodal

CRu

+

88.1

CR

2

II

-

DLBCL

Nodal

PR

-

92.2

CR

3

IV

-

DLBCL

Bone/bone marrow

SD

-

94.5

CR

4

II

-

Follicular grade 2

Nodal

CR

+

*

CR

5

IV

B

DLBCL

Nodal

CRu

+

60.8

CR

6

IV

B

DLBCL

Nodal

CRu

+

*

CR

7

II

-

Burkitt

Nodal

CR

-

97.2

CR

8

III

-

ALCL

Nodal

CR

+

47.8

Relapse

9

I

B

Burkitt

Nodal

CRu

+

91.2

CR

10

IV

B

Burkitt

Nodal

CR

-

95.2

CR

11

IV

-

Burkitt

Nodal

CRu

+

90.5

Relapse

12

II

B

ALCL

Nodal

CRu

-

95.8

CR

13

IV

-

Lymphoblastic

Nodal

PR

+

88.5

Relapse

14

III

-

ALCL

Nodal

CRu

+

34.1

CR

15

III

B

Burkitt

Extra nodal (stomach)

CR

+

50.7

CR

16

IV

B

Burkitt

Nodal

CR

+

92.5

CR

17

I

-

DLBCL

Nodal

CR

-

95.8

Relapse

18

IV

-

Burkitt

Nodal

CR

-

93.5

CR

  1. -, negative; +, positive; *, censored from analyses due to violation against imaging protocol (prolonged tracer uptake time at time point of staging, n = 2); B, bulky disease present; CIM, conventional imaging modalities; CR, complete response, CRu, complete response unconfirmed; PET, positron emission tomography; PR, partial response; SD, stable disease.